<div id="readability-page-1"><div><p>Dannuo Pharmaceutical (06872.HK), a biotechnology company approaching commercialization, announced details of its IPO, proposing a global offering of 8.2806 million H shares, of which around 10% will be offered in Hong Kong and around 90% internationally. The offer price is HKD75.7 per share. Based on a board lot of 50 shares, the entry fee per lot is approximately HKD3,823.17. The stock will start its public offering today (May 14) and close at noon next Tuesday (May 19), with listing expected next Friday (May 22). Joint sponsors are CITIC Securities and ABCI.</p><p>The IPO has attracted five cornerstone investors, including AMR Action Fund, L.P., AMR Action Fund, SCSp, Huayuan Management Consulting (Hong Kong), Orient Asset Management (Hong Kong) and Junsheng Global, subscribing for shares equivalent to approximately USD29.8 million (approximately HKD234 million) in aggregate.</p><p>WUXI APPTEC (02359.HK)<span> </span><span> -3.700 (-2.695%)  </span> <span> Short selling $122.45M; Ratio 20.510%  </span>  is a long-standing investor of the company. Upon completion of the global offering, WUXI APPTEC will hold approximately 5.5% of the companys total issued share capital through WuXi Fund.</p><p>The company expects to raise net proceeds of approximately HKD558 million from the listing. About 71% will be used for the research, development, registration filing and commercialization of its core products; 7% will fund the Phase IIb MRCT for the oral formulation of TNP-2092 for the treatment of HE, which is expected to commence in 2H27; 7.3% will be allocated to R&amp;D of other pipeline candidates; 7.2% will be used to build its own manufacturing facility in Zhongshan, Guangdong Province; and 7.5% will be used for working capital and general corporate purposes.</p><p>Dannuo Pharmaceutical is a biotechnology company focused on bacterial infections and bacterial metabolism-related diseases. It has established a pipeline of seven innovative projects, including two core products. Rifotnizole (TNP-2198), a new molecular entity candidate, is used in China and the US as part of triple therapy in combination with amoxicillin and PPI for the treatment of Helicobacter pylori infection, and is also being developed in China as a monotherapy for bacterial vaginosis and Clostridioides difficile infection. Riforoquinone (TNP-2092 injection) is a triple-target candidate for the treatment of implant-related bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and prosthetic joint infections (PJI), as well as left ventricular assist device infections (LVADI) and catheter-related bloodstream infections (CRBSI) in China and the US. (jl/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-13 16:25.)</p></div></div>

02359

520690

159837

562050

516500

520880

512010

<p>Dannuo Pharmaceuticalhas launched its IPO today, offering 8.2806 million H shares at HKD75.7 each, with an entry fee of HKD3,823.17 per lot. The public offering will close on May 19, and listing is expected on May 22. The company aims to raise approximately HKD558 million, primarily for R&D and commercialization of its products. WUXI APPTEC is a cornerstone investor, holding about 5.5% of the company post-offering. Dannuo focuses on bacterial infections and has a pipeline of seven innovative projects, including two core products for treating various infections.</p>

AASTOCKS News

WUXI APPTEC

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

CITIC SEC

CITIC Securities Co., Ltd.

Orient Corporation

WuXi AppTec

Dannuo Pharmaceutical  Starts IPO Today; Entry Fee HKD3,823.17 per Lot; WUXI APPTEC Participates in Early-stage Investment